Click to see Portfolio
Click to see Portfolio
Click to see Portfolio
Click to see Portfolio
Click to see Portfolio
Click to see Portfolio
Click to see Portfolio
Janitri has received BIRAC SIIP Fellowship, BIRAC IIPME & SBIRI Grant. The company has been granted seven patents filed in India.
Bengaluru, India
Health
Maternal and child health
Janitri has received BIRAC SIIP Fellowship, BIRAC IIPME & SBIRI Grant. The company has been granted seven patents filed in India.
Every year, 2 Million Neonatal & 250,000 Maternal deaths occur during the intra-partum period globally. In India, more than 80% of deliveries occur with the assistance of staff nurses in a low resource healthcare setting, which lacks skilled healthcare workers and medical devices. There is a need for affordable & accurate solutions designed for low skilled healthcare workers, which would help them in accurate monitoring and decision support during the intra-partum period.
KEYAR is an affordable and super easy to use patch-based wearable maternal-fetal monitoring device for the intrapartum period, which also communicates with DAKSH intrapartum monitoring mobile application for intelligent alerts and remote monitoring. The product is for the staff nurses/midwives/doctors, which help them in monitoring the mother and fetus during labor phase. The intelligent alerts also help them in making early decisions, which eventually save lives during the labor phase.
The innovation empowers low skilled healthcare workers during the intra-partum period for better monitoring and decision making to prevent maternal & newborn mortality/morbidity. Till date, more than 30,000 pregnant women monitored during the intrapartum period using Janitri solutions.
Yostra has received BIG Grant, SBIRI, and Sparsh Grant. It has been granted patent towards the device for Dermatological & Sub-cutaneous Tissue Treatment
Bengaluru, India
Health
Diabetes screening and treatment
Yostra has received BIG Grant, SBIRI, and Sparsh Grant. It has been granted patent towards the device for Dermatological & Sub-cutaneous Tissue Treatment
India has approximately 69 million diabetic patients. About 30% of diabetics develop diabetic peripheral neuropathy, and half of those will develop foot ulcers due to their condition. The poor are significantly at risk because of inadequate management of their condition. There is a critical need for affordable diagnostic devices to enable mass screening of diabetic patients for peripheral neuropathy, as well as a need for affordable treatment options for diabetic foot ulcers.
Kadam is a medical device developed for the treatment of Diabetic Foot Ulcers. The medical equipment in the proposed therapy involves exposing the patient’s foot with diabetes to a constant stream of warm oxygen inside a disposable therapy bag. Kadam consists of a warmer unit and a therapy bag which is used along with an off the shelf oxygen concentrator.
The proposed diabetic foot ulcer treatment method & the medical equipment developed will reduce hospital admissions of patients with diabetic foot ulcers. Kadam can potentially prevent 2 Lakh amputation per year in India. It will drastically reduce the cost of treatment of diabetic foot ulcer compared to existing therapies or equipment used
Bengaluru, India
Bengaluru, India
Health
Biotechnology, diagnostics
Infectious diseases constitute nearly 50% of the disease burden in India and much higher than 50% in people at the base of the pyramid and children below the age of 5. Delay in diagnosis and late or inappropriate treatment increases the risk of complications, higher morbidity, and mortality and increased cost to the patient.
OmiX Labs is developing a novel technology platform that allows for DNA testing for pathogens, outside of laboratory settings. Analogous to the glucose strips and glucometer devices for glucose testing at home, the OmiX platform detects pathogen DNA present in a few drops of blood on a novel disposable biochip, with a proprietary enrichment and assay on the chip and a reader for DNA analysis.
The platform is designed to bring advances in molecular diagnosis and create access where there is none: mostly in lower-income groups who do not have access to laboratories and yet need early and accurate detection to have a better chance for cure.
Bengaluru, India
Health
The first 28 days of life are the most vulnerable time for a child’s survival. Globally, 2.6 million children died in the first month of life in 2016 – approximately 7,000 newborn deaths every day – most of which occurred in the first week, with about 1 million dying on the first day and close to 1 million dying within the next six days. In India, approximately 8 million clinically low birth weight babies are born every year. These babies are susceptible to a variety of life threatening conditions like Apnea, Hypothermia and Respiratory Distress – causing either death or some form of morbidity.
Almost all of these deaths are preventable with timely treatment. However, hospitals in the developing world are severely challenged by limited resources.They cannot afford the expensive equipment, which are also too bulky and unsuitable for continuous monitoring and they have a high rate of false alarms; forcing nurses to visually monitor the babies.In low resource settings where one nurse cares for about 40 babies,she will not be able to give equal attention to every baby and thereby most of the distress conditions often go unnoticed, causing irreversible injury to the newborn and sometimes even lead to the death.In the current situation if child has to be monitored they have to be kept in a separate room and hooked on to wires – which hinders breastfeeding and kangaroo mother care – which in turn hinders the growth and recovery. There is an urgent need for a tool to enable these overloaded healthcare workers to monitor and diagnose the above mentioned conditions more accurately and provide timely treatment.
The Nemocare Raksha is an IoT enabled smart wearable on the baby’s foot which monitors vital parameters like spo2, Heart Rate,Respiration Rate ,body temperature, body position that will give the complete picture of the baby’s health. And all the information is relayed over to the hub and the data is pushed onto the cloud and this data can be accessed at a central monitor by which the nurse or doctor can continuously and remotely monitor all the babies through a single interface
The entire system along with our deep learning algorithm works as an intelligent platform that will track the baby’s health in the most accurate way possible and give only insightful notifications and alerts to healthcare workers to enable timely intervention when a distress condition is detected.
This platform will help collect, store, visualize and analyse the data generated. This can enable a paradigm shift in clinical diagnostics and preventive care through a data driven approach.Inherently the data is used in real time to provide early warning scores and other predictive indicators, and is used offline to develop new predictive algorithms.
In the next 5 years we intend to monitor and save 900,000 babies through 21,000 of our devices deployed. And soon we hope to be an integral part of India – where no child ever dies of a cause that is completely preventable
Clinical Trials for TB partially completed (NH/MSMF Bangalore & Telangana (Gadwal & Warangal Districts). AGlobal Pilot for ncovid19 under the auspices of Social Alpha demonstrating promising results when implicitly validated with a RT-PCR.
—
—
Health
—
Clinical Trials for TB partially completed (NH/MSMF Bangalore & Telangana (Gadwal & Warangal Districts). AGlobal Pilot for ncovid19 under the auspices of Social Alpha demonstrating promising results when implicitly validated with a RT-PCR.
A simple and straightforward screening test doesn’t exist for PTB which often relies on a Protocol/Algorithm involving CXR, Smear Microscopy, CBNAAT and Culture. We initially plan to introduce TimBre to fit in the protocol.
An AI/Machine-Learning based solution that leverages underlying annotated data from an entire spectrum of Lung Based Ailments offering Non-Invasive (Acoustics of Cough), Point of Care (anytime & anywhere) & in realtime (Results that are interpretable/explainable).
Improving Active Case Finding for TB to meet the SDGs of 2025 End TB goal in India and other countries with varying deadlines, Solution is primarily targeted as a low-cost solution for BoP (India, Indonesia, Africa), Addressing easy and early detection of TB and ncovid19 with an extended usage for Prognosis.
Got funding from BPCL. Partnered with Capgemini and Google. On boarded well known cardiologists as advisors and board members.
—
Bengaluru, India
Health
—
Got funding from BPCL. Partnered with Capgemini and Google. On boarded well known cardiologists as advisors and board members.
The problem we are addressing is that for patients with asymptomatic symptoms like syncope, palpitation, dizziness etc the
detection of arrhythmia could be missed with 24 hour monitoring. We are trying to fill this gap in the cardiology segment.
We combine wearable biosensing technologies with machine learning and AI capabilities to provide remote cardiac monitoring to masses.
We helps to provide affordable healthcare solutions to even under privileged people. Our solution will take the pressure of clinicians and patients while enhancing patient care to masses.
Thermaissance is a nanotechnology-based technical textiles startup. A smart textiles venture that reduces various healthcare-associated and community-acquired infections. Scientifically proven to be effective against enveloped viruses (including coronavirus), gram positive bacteria, gram negative bacteria, MRSA, VRE, CRE and mucor species. We make various medical textiles such as scrubs, gowns, patient clothing, lab coats, etc using these fabrics.
